Is personalised medicine the future? EU-backed project to map 100,000 genomes

Could a medicine one day be designed on the basis of the genetic characteristics of the person who is going to take it? Could doctors know in advance which patients are more likely to respond to a treatment...
Could a medicine one day be designed on the basis of the genetic characteristics of the person who is going to take it?
Could doctors know in advance which patients are more likely to respond to a treatment or to develop side effects?
And could the genetic causes of diseases that are currently hard to diagnose be identified more easily?
Personalised medicine is no longer just a distant scientific vision. Some of its applications are already used in clinical practice, while wider deployment requires much more knowledge of the human genome.
The Genome of Europe programme is one of the largest European population genomics projects. In total, 49 partners from 27 European countries are working together to create a shared reference base of at least 100,000 human genomes, which will reflect the genetic diversity of European populations.
The programme has a budget of €45 million, of which €20 million come from the European Commission through the Digital Europe programme. The project officially started in the autumn of 2024 and is scheduled to run for 3.5 years.
Cyprus is taking part in this effort through the Centre of Excellence for Biobanking and Biomedical Research biobank.cy at the University of Cyprus. Its contribution includes sequencing the whole genome of at least 310 Cypriot volunteers, feeding into the European reference base.
Why Europe needs a genetic map
Human DNA is, to a large extent, shared by all of us. However, small genetic differences are important for understanding inheritance, predisposition to certain diseases and, in specific cases, how people respond to medicines.
These differences are not distributed in the same way across all populations. This means that a genetic database built mainly from specific population groups may not adequately capture the genetic diversity of others.
Genome of Europe aims to close this gap by creating a representative European dataset that can be used as a reference point for future research.
"Populations, such as that of Cyprus, have their own specific characteristics," explained Katerina Strati, an associate professor in the biological sciences department at the University of Cyprus.
She told Euronews that understanding the genome at the local level is essential, because the relevant information cannot simply be inferred from research in other populations.
For scientists, a reference genome acts as a yardstick. It allows them to examine the genetic variants they identify in a person and to assess how common or rare they are in the population to which that person belongs.
Cyprus maps its own DNA
Mapping the Cypriot genome in its current form began in 2019, Strati explains. The aim is to create a genetic reference background for the country’s population, which will support medical research and molecular diagnosis.
Under the Cypriot Human Genome Project (CYPROME), more than 1,000 exomes from Cypriot volunteers have already been analysed. The exome is the part of the genome that includes the protein-coding regions of genes. Its analysis differs from sequencing the whole genome, which examines a much larger section of DNA.
Apostolos Malatras, a senior bioinformatician at the Centre of Excellence biobank.cy, explained that creating a reference genome allows researchers to compare genetic findings against a common background.
Today, biobank.cy holds more than 123,000 biological samples, involves 12,257 volunteers and is active in 14 research programmes, according to the figures published on its website.
The samples do not correspond one to one to genomes or participants. A volunteer can provide more than one sample, and DNA sequencing is a separate process.
Studies carried out at the Cyprus Biobank focus on hereditary kidney diseases, heart conditions and other illnesses. Its research programmes also include efforts to develop preclinical models for rare kidney diseases such as Alport syndrome.
Mariel Voutounou, a project manager at the Centre of Excellence, described the search for a treatment as a long and demanding marathon.
"When a doctor or scientist is interested in starting research into a condition, we say that they are starting a time-consuming marathon. And that is because it takes a great deal of time and effort to collect all these data and samples," Voutounou said. "Someone who has a whole biobank and this wealth of information in their toolbox, we say that their starting line is 10 kilometres ahead of everyone else."
Who protects patients’ DNA?
DNA contains highly sensitive information, not only about a person’s health but also about their biological relatives. How is it ensured that the genetic data of thousands of volunteers will not be used without their knowledge or consent?
The Cyprus Biobank operates with the approval of the National Bioethics Committee of Cyprus and in accordance with the European General Data Protection Regulation (GDPR). As Malatras explains, biobank.cy applies multiple layers of technical and organisational security, with restricted access to personal data.
Dr Georgia Charalambidou, who is responsible for ethical, legal and social issues (ELSI) and education at the centre, explained that protection begins even before the first sample is collected.
"When a volunteer, an individual, comes here to the centre, the first thing we do is to provide them with sufficient information," Charalambidou said. "We try to make sure that they have understood it. We give them time to process it, to ask us questions and of course a consent form is always signed, in which all their rights are recorded."
Participation remains voluntary even after signing. "We always explain that they can withdraw their consent at any time, without any impact," Charalambidou stressed, clarifying that in the case of patients this decision does not affect their treatment or their relationship with their treating doctor.
The centre has also carried out a survey involving around 569 Cypriots, examining their views on genetic tests and taking part in genetic research.
According to Charalambidou, most participants were positive towards genetic research but want transparency and information about how their data are used. At the same time, they are interested in being able to receive results from the studies in which they take part.
"They want to know how we handle their data, what results exist. They also want to get something back," she said.
She noted that those who had been in contact with patients with diagnosed conditions were more positive about receiving genetic results back from specialist doctors. This finding, she added, highlights the need for better public information on genetic research.
Data work together without travelling
How can scientists in different countries use genetic data without putting their security at risk?
This is what the European Genomic Data Infrastructure (GDI) programme aims to ensure. It works alongside Genome of Europe, creating infrastructure for the secure interconnection of genetic data.
As Malatras explained, researchers will be able to carry out analyses on the systems where the data are stored, without the files themselves needing to be transferred from country to country.
This cooperation is particularly important for rare diseases, as it allows genetic findings from different populations to be compared.
Precision medicine is already used in some treatments, especially in oncology. However, the development of medicines tailored to the genetic characteristics of each patient remains a long-term prospect.
This is also the ambition behind the European collaboration: that the knowledge now being gathered from the DNA of thousands of volunteers will help deliver better diagnoses, more effective prevention and treatments tailored to patients’ needs.




